New treatments for Parkinson’s disease include longer-acting levodopa medicines, medicines delivered through a small pump, and procedures such as deep brain stimulation or focused ultrasound for selected movement problems. These options can help control symptoms when standard tablets do not last long enough or cause difficult side effects. Research into cell replacement, gene-based treatments, and therapies aimed at disease processes is advancing, but none is yet a proven cure.
Recent progress in Parkinson’s treatment is making it possible to manage certain symptoms more consistently and tailor treatment to individual needs. Some advances involve improved ways to deliver established medicines, while others use targeted procedures or experimental approaches designed to protect or replace affected brain cells. The right option depends on symptoms, medication response, overall health, treatment goals, and which therapies are available in the person’s country.
What are the newest treatments for Parkinson's disease?
Several developments are particularly important for people whose symptoms become harder to control with standard tablets. In the United States, newer options include extended-release carbidopa/levodopa capsules and continuous medication delivered under the skin through a pump. Focused ultrasound has also expanded as a treatment for selected movement problems. These approaches serve different purposes, and a newer treatment is not necessarily better than an existing one for every person.
1. Extended-release carbidopa/levodopa
Levodopa is a medicine that the brain uses to make dopamine, a chemical messenger involved in controlling movement. It remains one of the most effective medicines for Parkinson’s motor symptoms. Carbidopa is combined with levodopa to help more of the levodopa reach the brain and reduce certain side effects.
Newer formulations aim to release the medicine over a longer period. One example is Crexont, an extended-release carbidopa/levodopa capsule approved for adults in the United States in 2024. The U.S. Food and Drug Administration (FDA) prescribing information for Crexont describes a formulation that maintains levodopa levels over several hours after a dose. Its actual effect on symptoms and the time between doses varies between individuals.
Extended-release treatment may be useful when symptoms return before the next dose or when a more convenient dosing schedule is a priority. However, these capsules do not eliminate all fluctuations, and some people may still need other medicines or treatment adjustments. The dose cannot be changed safely by simply substituting the same number of milligrams from another formulation, so any switch should be planned with the prescribing clinician.
2. Continuous levodopa infusion through a small pump
Some people with advanced Parkinson’s experience periods when medication works well, known as “on” time, followed by periods when movement symptoms return, known as “off” time. These fluctuations can become difficult to manage even after tablets have been adjusted. Continuous medication delivery is designed to provide a steadier supply of treatment throughout the day.
One newer option is Vyalev, a combination of foscarbidopa and foslevodopa. The FDA approved it in October 2024 for adults with advanced Parkinson’s disease who experience motor fluctuations. A portable pump delivers the medicine continuously through a small tube placed under the skin. The body converts the medication into the active forms of carbidopa and levodopa.
Unlike tablet-based treatment, this approach does not depend on taking each dose by mouth at a particular time. It may help people who have significant periods of reduced movement control between oral doses. Nevertheless, it requires training and regular care of the infusion site. Skin reactions and infections can occur, and other possible adverse effects include hallucinations and involuntary movements. The FDA prescribing information for Vyalev provides further details about its intended use and safety precautions.
3. Other treatments for sudden “off” periods
Not every new treatment requires a permanent change to the daily medication plan. Certain established medicines, including inhaled levodopa and apomorphine given by injection, can be used as additional or rescue treatments for selected people when movement symptoms suddenly return. They act differently from routine tablets and may help address specific episodes rather than provide all-day symptom control.
These options are not suitable for everyone. The choice depends on how often episodes occur, other medicines being taken, possible side effects, and whether the person can use the delivery device correctly. A neurologist can explain whether a rescue treatment or a longer-acting medication approach better matches the pattern of symptoms.
Can brain procedures offer better symptom control?
When medication adjustments are no longer enough, certain procedures may improve movement symptoms. They do not cure Parkinson’s disease or stop the underlying disease process. Their benefits and risks also differ: some procedures can be adjusted after treatment, while others permanently change a small, targeted area of brain tissue.
Deep brain stimulation
Deep brain stimulation (DBS) is an established surgical treatment rather than a brand-new therapy, but it remains an important option as treatment technology develops. A surgeon places thin electrodes in specific areas of the brain and connects them to a device that sends electrical pulses. These signals can help reduce selected movement symptoms, including tremor, stiffness, slowness, involuntary movements, and fluctuations in medication response.
DBS is usually considered when medication provides an inconsistent response or causes difficult movement-related complications. It requires surgery, follow-up visits, and adjustments to the stimulation settings. It does not reliably improve every Parkinson’s symptom, and problems with balance, speech, swallowing, or thinking may affect whether it is appropriate. The Parkinson’s Foundation guide to surgical treatment options explains how DBS compares with other advanced approaches.
Focused ultrasound
Focused ultrasound uses concentrated sound waves, guided by magnetic resonance imaging, to heat a small, carefully selected area of brain tissue involved in movement. The procedure does not require the surgical placement of electrodes. Depending on the technique and treatment target, it can reduce certain symptoms, including tremor and other medication-resistant motor complications.
In the United States, the FDA has expanded the approved uses of focused ultrasound for selected Parkinson’s-related movement problems, including staged treatment of both sides of the brain in eligible patients. Suitability depends on the specific procedure, the symptoms being treated, and individual clinical factors.
An important difference between focused ultrasound and DBS is that ultrasound-based lesion treatment creates a permanent change in the targeted tissue. Unlike electrical stimulation, that lesion cannot be switched off or adjusted afterward. Possible complications include balance difficulties, weakness, numbness, and speech problems. These risks need careful discussion before a person chooses the procedure.
Focused ultrasound may be an option for some people who are not suitable candidates for DBS or who prefer a procedure without implanted stimulation hardware. It is not appropriate for every form of Parkinson’s disease, and it does not address all movement or non-movement symptoms.
Could future treatments slow or reverse Parkinson’s disease?
Most currently available Parkinson’s treatments focus on relieving symptoms. Researchers are working on a different goal: treatments that could change the disease process itself by slowing the loss of dopamine-producing brain cells, protecting affected cells, or replacing cells that have been lost. These are known as disease-modifying or cell-replacement approaches. They remain areas of active research rather than established cures.
Stem cell therapy and replacement of dopamine-producing cells
Parkinson’s disease involves the loss of brain cells that produce dopamine. Stem cell research aims to create replacement cells that can develop into dopamine-producing neurons and potentially restore some of the function that has been lost. Early clinical studies have investigated whether transplanted cells can survive and help improve movement symptoms.
These studies are encouraging enough to support further research, but important questions remain about long-term safety, how well transplanted cells function, how durable any improvement may be, and who might benefit. Stem cell treatment is not an established cure, and there is currently no routinely approved stem cell therapy that can be recommended as standard Parkinson’s care. The Parkinson’s Foundation’s September 2026 review of disease-modifying research and stem cells describes current research directions and the need for carefully conducted trials.
Gene therapy and treatments aimed at alpha-synuclein
Researchers are also testing gene-based approaches that may help affected brain cells produce useful substances or support dopamine-related pathways. Some studies focus on particular genetic changes associated with Parkinson’s disease. These approaches could eventually support more personalized treatment, but the benefits and risks depend on the specific therapy and are still being studied.
Another major research area involves alpha-synuclein, a protein associated with Parkinson’s disease that can form abnormal clumps in the brain. Scientists are exploring treatments intended to reduce the production of this protein, prevent abnormal clumping, or limit its spread. These approaches are designed to address processes associated with the disease rather than simply replace dopamine, but it remains uncertain which strategies, if any, will lead to broadly effective treatments.
Other medicines being investigated
Researchers are testing several medicines that were initially developed for other purposes, including some drugs that act on pathways involved in diabetes and metabolism. They are also studying the relationship between the gut and the brain, inflammatory processes, and treatments tailored to genetic findings. These ideas are scientifically promising, but a treatment that works in laboratory studies or an early clinical trial is not necessarily safe or effective in routine care.
The National Institute of Neurological Disorders and Stroke (NINDS) explains that available medicines and procedures can help manage Parkinson’s symptoms, while researchers continue to investigate ways to address the disease itself. At present, no treatment has been established as a cure or as a reliably effective way to stop Parkinson’s disease from progressing.
What recent medication safety information should patients know?
New treatment decisions also involve understanding the safety of medicines that are already widely used. In March 2026, the FDA announced updated warnings for medicines containing carbidopa and levodopa because they can cause vitamin B6 deficiency and associated seizures. The FDA advises healthcare professionals to check vitamin B6 levels before treatment and periodically during treatment, and to provide supplementation when necessary.
This warning does not mean that people should stop taking levodopa or start taking vitamin B6 supplements on their own. Anyone using these medicines should discuss monitoring with the prescribing clinician, particularly before making changes to treatment. The FDA’s March 2026 drug safety communication provides the details of this update.
How can you decide whether a newer Parkinson’s treatment is appropriate?
The most useful treatment is the one that addresses a person’s particular symptoms and goals while offering an acceptable balance of benefits, risks, and practical demands. A movement-disorders specialist may review how long each dose works, when symptoms return, whether involuntary movements develop, and whether difficulties with walking, balance, thinking, sleep, or other functions affect treatment choices.
Before considering an infusion pump or brain procedure, it can help to record medication times, periods when movement improves or worsens, side effects, and activities that become difficult. This information can make it easier to identify patterns and compare options. Questions about daily device management, follow-up care, potential complications, costs, and local access are also important.
Access varies by country, and a medicine or procedure approved in one region may not yet be approved or widely available in another. If an experimental therapy sounds promising, ask whether it is part of a properly reviewed clinical trial and discuss the study with a qualified clinician. Be cautious of clinics promising a cure, particularly those that charge for unproven stem cell procedures or claim that research results guarantee an individual benefit.
New treatments offer additional ways to manage Parkinson’s symptoms, especially when standard medication schedules become difficult to maintain. Longer-acting medicines, continuous infusions, DBS, and focused ultrasound each have different roles. Stem cell, gene-based, and disease-modifying approaches may expand future options, but they require further evidence before they can be considered established treatments.